Opus Genetics advances five gene therapy programs with four clinical data readouts expected in 2027

Opus Genetics highlighted its expanding pipeline for inherited retinal diseases with three new programs entering clinical testing over the next 12-18 months and cash runway extending into 2029. The company's first-mover advantage across multiple rare disease indications and potential for Priority Review Vouchers positions it for multiple clinical inflection points and potential product approvals.